Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSS0393 ointment and SHR0302 Base gel in adult non-segmental vitiligo
ChiCTR2600127232Phase 2Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RSS0393 and ivarmacitinib in Vitiligo (3 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: F-VASI50 response at end of treatment. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
RSS0393ivarmacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2600127232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127232.